These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34263354)

  • 1. Effects of head trauma and sport participation in young-onset Parkinson's disease.
    Schirinzi T; Grillo P; Di Lazzaro G; Zenuni H; Salimei C; Dams-O'Connor K; Sancesario GM; Mercuri NB; Pisani A
    J Neural Transm (Vienna); 2021 Aug; 128(8):1185-1193. PubMed ID: 34263354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Young-onset and late-onset Parkinson's disease exhibit a different profile of fluid biomarkers and clinical features.
    Schirinzi T; Di Lazzaro G; Sancesario GM; Summa S; Petrucci S; Colona VL; Bernardini S; Pierantozzi M; Stefani A; Mercuri NB; Pisani A
    Neurobiol Aging; 2020 Jun; 90():119-124. PubMed ID: 32169356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
    Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
    Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of sleep in young onset Parkinson's disease: Any difference from older onset Parkinson's disease.
    Mahale R; Yadav R; Pal PK
    Parkinsonism Relat Disord; 2015 May; 21(5):461-4. PubMed ID: 25744440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Better quality of life and less caregiver strain in young-onset Parkinson's disease: a multicentre retrospective cohort study.
    Te Groen M; Bloem BR; Wu SS; Post B;
    J Neurol; 2021 Mar; 268(3):1102-1109. PubMed ID: 33108538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.
    Goldman JG; Andrews H; Amara A; Naito A; Alcalay RN; Shaw LM; Taylor P; Xie T; Tuite P; Henchcliffe C; Hogarth P; Frank S; Saint-Hilaire MH; Frasier M; Arnedo V; Reimer AN; Sutherland M; Swanson-Fischer C; Gwinn K; ; Kang UJ
    Mov Disord; 2018 Feb; 33(2):282-288. PubMed ID: 29205509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of non-motor symptoms in young-onset versus late-onset Parkinson's disease.
    Spica V; Pekmezović T; Svetel M; Kostić VS
    J Neurol; 2013 Jan; 260(1):131-7. PubMed ID: 22820720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Environmental risk factors of young onset Parkinson's disease: a case-control study.
    Tsai CH; Lo SK; See LC; Chen HZ; Chen RS; Weng YH; Chang FC; Lu CS
    Clin Neurol Neurosurg; 2002 Sep; 104(4):328-33. PubMed ID: 12140099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subthalamic nucleus deep brain stimulation outcome in young onset Parkinson's disease: a role for age at disease onset?
    Merola A; Zibetti M; Artusi CA; Marchisio A; Ricchi V; Rizzi L; Angrisano S; Arduino N; Lanotte M; Rizzone M; Lopiano L
    J Neurol Neurosurg Psychiatry; 2012 Mar; 83(3):251-7. PubMed ID: 22180646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Study of 668 Indian Subjects with Juvenile, Young, and Early Onset Parkinson's Disease.
    Kukkle PL; Goyal V; Geetha TS; Mridula KR; Kumar H; Borgohain R; Mukherjee A; Wadia PM; Yadav R; Desai S; Kumar N; Gupta R; Biswas A; Pal PK; Muthane U; Das SK; Quinn N; Ramprasad VL;
    Can J Neurol Sci; 2022 Jan; 49(1):93-101. PubMed ID: 33685545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.
    Abbasi N; Mohajer B; Abbasi S; Hasanabadi P; Abdolalizadeh A; Rajimehr R
    Mov Disord; 2018 Mar; 33(3):431-439. PubMed ID: 29436735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
    Delgado-Alvarado M; Gago B; Gorostidi A; Jiménez-Urbieta H; Dacosta-Aguayo R; Navalpotro-Gómez I; Ruiz-Martínez J; Bergareche A; Martí-Massó JF; Martínez-Lage P; Izagirre A; Rodríguez-Oroz MC
    Mov Disord; 2017 Jul; 32(7):1066-1073. PubMed ID: 28548309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
    Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM;
    JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal fluid beta-amyloid levels in Parkinson disease.
    Ibanez L; Bahena JA; Yang C; Dube U; Farias FHG; Budde JP; Bergmann K; Brenner-Webster C; Morris JC; Perrin RJ; Cairns NJ; O'Donnell J; Álvarez I; Diez-Fairen M; Aguilar M; Miller R; Davis AA; Pastor P; Kotzbauer P; Campbell MC; Perlmutter JS; Rhinn H; Harari O; Cruchaga C; Benitez BA
    Acta Neuropathol Commun; 2020 Nov; 8(1):196. PubMed ID: 33213513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.
    Hall S; Surova Y; Öhrfelt A; ; Blennow K; Zetterberg H; Hansson O
    Mov Disord; 2016 Jun; 31(6):898-905. PubMed ID: 26878815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels.
    Ibanez L; Dube U; Saef B; Budde J; Black K; Medvedeva A; Del-Aguila JL; Davis AA; Perlmutter JS; Harari O; Benitez BA; Cruchaga C
    BMC Neurol; 2017 Nov; 17(1):198. PubMed ID: 29141588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report.
    Gao R; Zhang G; Chen X; Yang A; Smith G; Wong DF; Zhou Y
    PLoS One; 2016; 11(10):e0164762. PubMed ID: 27764160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's Disease.
    Oosterveld LP; Kuiper TI; Majbour NK; Verberk IMW; van Dijk KD; Twisk JWR; El-Agnaf OM; Teunissen CE; Weinstein HC; Klein M; Berendse HW; van de Berg WDJ
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson's disease.
    Murakami H; Tokuda T; El-Agnaf OMA; Ohmichi T; Miki A; Ohashi H; Owan Y; Saito Y; Yano S; Tsukie T; Ikeuchi T; Ono K
    BMC Neurol; 2019 Jun; 19(1):113. PubMed ID: 31164098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.